## An-Wen Chan

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4549185/publications.pdf

Version: 2024-02-01

71 papers 28,631 citations

28 h-index 98622 67 g-index

72 all docs 72 docs citations

times ranked

72

41965 citing authors

#	Article	IF	CITATIONS
1	ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ, The, 2016, 355, i4919.	3.0	8,654
2	Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ, The, 2014, 348, g1687-g1687.	3.0	5,661
3	SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials. Annals of Internal Medicine, 2013, 158, 200.	2.0	4,463
4	SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ, The, 2013, 346, e7586-e7586.	3.0	3,435
5	Empirical Evidence for Selective Reporting of Outcomes in Randomized Trials. JAMA - Journal of the American Medical Association, 2004, 291, 2457.	3.8	1,509
6	Biomedical research: increasing value, reducing waste. Lancet, The, 2014, 383, 101-104.	6.3	750
7	Increasing value and reducing waste: addressing inaccessible research. Lancet, The, 2014, 383, 257-266.	6.3	692
8	Identifying outcome reporting bias in randomised trials on PubMed: review of publications and survey of authors. BMJ: British Medical Journal, 2005, 330, 753.	2.4	489
9	Epidemiology and reporting of randomised trials published in PubMed journals. Lancet, The, 2005, 365, 1159-1162.	6.3	407
10	Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI extension. Nature Medicine, 2020, 26, 1364-1374.	15.2	353
11	Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI extension. Nature Medicine, 2020, 26, 1351-1363.	15.2	251
12	SPIRIT 2013: new guidance for content of clinical trial protocols. Lancet, The, 2013, 381, 91-92.	6.3	226
13	Guidelines for Reporting Trial Protocols and Completed Trials Modified Due to the COVID-19 Pandemic and Other Extenuating Circumstances. JAMA - Journal of the American Medical Association, 2021, 326, 257.	3.8	168
14	Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI Extension. BMJ, The, 2020, 370, m3210.	3.0	157
15	Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI extension. The Lancet Digital Health, 2020, 2, e549-e560.	5.9	135
16	Research Techniques Made Simple: Assessing Risk of Bias in Systematic Reviews. Journal of Investigative Dermatology, 2016, 136, e109-e114.	0.3	133
17	SPIRIT 2013 Statement: defining standard protocol items for clinical trials. Revista Panamericana De Salud Publica/Pan American Journal of Public Health, 2015, 38, 506-14.	0.6	114
18	Outcome reporting bias in trials: a methodological approach for assessment and adjustment in systematic reviews. BMJ: British Medical Journal, 2018, 362, k3802.	2.4	83

#	Article	IF	CITATIONS
19	Systematic review of melanoma incidence and prognosis in solid organ transplant recipients. Transplantation Research, 2014, 3, 10.	1.5	66
20	SPIRIT-PRO Extension explanation and elaboration: guidelines for inclusion of patient-reported outcomes in protocols of clinical trials. BMJ Open, 2021, 11, e045105.	0.8	65
21	Standard Protocol Items for Clinical Trials with Traditional Chinese Medicine 2018: Recommendations, Explanation and Elaboration (SPIRIT-TCM Extension 2018). Chinese Journal of Integrative Medicine, 2019, 25, 71-79.	0.7	64
22	Association of Trial Registration With Reporting of Primary Outcomes in Protocols and Publications. JAMA - Journal of the American Medical Association, 2017, 318, 1709.	3.8	55
23	Guidelines for randomized clinical trial protocol content: a systematic review. Systematic Reviews, 2012, 1, 43.	2.5	53
24	SPIRIT extension and elaboration for n-of-1 trials: SPENT 2019 checklist. BMJ, The, 2020, 368, m122.	3.0	45
25	Promoting public access to clinical trial protocols: challenges and recommendations. Trials, 2018, 19, 116.	0.7	44
26	Bias in reporting of randomised clinical trials in oncology. European Journal of Cancer, 2016, 61, 29-35.	1.3	42
27	A randomized-controlled trial of nabilone for the prevention of acute postoperative nausea and vomiting in elective surgery. Canadian Journal of Anaesthesia, 2017, 64, 385-395.	0.7	41
28	Reporting guidelines for clinical trials of artificial intelligence interventions: the SPIRIT-AI and CONSORT-AI guidelines. Trials, 2021, 22, 11.	0.7	35
29	Predicting skin cancer in organ transplant recipients: development of the <scp>SUNTRAC</scp> screening tool using data from a multicenter cohort study. Transplant International, 2019, 32, 1259-1267.	0.8	33
30	Improved keratinocyte carcinoma outcomes with annual dermatology assessment after solid organ transplantation: Population-based cohort study. American Journal of Transplantation, 2019, 19, 522-531.	2.6	30
31	Improving outcome reporting in clinical trial reports and protocols: study protocol for the Instrument for reporting Planned Endpoints in Clinical Trials (InsPECT). Trials, 2019, 20, 161.	0.7	28
32	Noncutaneous and Cutaneous Cancer Risk in Patients With Atopic Dermatitis. JAMA Dermatology, 2020, 156, 158.	2.0	27
33	Search for unpublished data by systematic reviewers: an audit. BMJ Open, 2017, 7, e017737.	0.8	24
34	Honorary and ghost authorship in reports of randomised clinical trials in oncology. European Journal of Cancer, 2016, 66, 1-8.	1.3	23
35	Outcome reporting recommendations for clinical trial protocols and reports: a scoping review. Trials, 2020, 21, 620.	0.7	23
36	Association between antihypertensive medications and risk of skin cancer in people older than 65 years: a population-based study. Cmaj, 2021, 193, E508-E516.	0.9	20

#	Article	IF	Citations
37	Gender disparity between authors in leading medical journals during the COVID-19 pandemic: a cross-sectional review. BMJ Open, 2021, 11, e051224.	0.8	19
38	Application of Recursive Partitioning to Derive and Validate a Claims-Based Algorithm for Identifying Keratinocyte Carcinoma (Nonmelanoma Skin Cancer). JAMA Dermatology, 2016, 152, 1122.	2.0	18
39	Systematic Review of Sexâ€Specific Reporting of Data: Cholinesterase Inhibitor Example. Journal of the American Geriatrics Society, 2017, 65, 2213-2219.	1.3	18
40	Comprehensive capture of cutaneous melanoma by the Ontario Cancer Registry: validation study using community pathology reports. Cancer Causes and Control, 2016, 27, 137-142.	0.8	15
41	Raising the Bar for Randomized Trials Involving Artificial Intelligence: The SPIRIT-Artificial Intelligence and CONSORT-Artificial Intelligence Guidelines. Journal of Investigative Dermatology, 2021, 141, 2109-2111.	0.3	15
42	Prospective reporting of statistical analysis plans for randomised controlled trials. Trials, 2020, 21, 898.	0.7	14
43	Guidelines for cellular and molecular pathology content in clinical trial protocols: the SPIRIT-Path extension. Lancet Oncology, The, 2021, 22, e435-e445.	5.1	13
44	Reliability of Trial Information Across Registries for Trials With Multiple Registrations. JAMA Network Open, 2021, 4, e2128898.	2.8	12
45	Incidence and mortality rates of keratinocyte carcinoma from 1998–2017: a population-based study of sex differences in Ontario, Canada. Cmaj, 2021, 193, E1516-E1524.	0.9	11
46	Blindsided: challenging the dogma of masking in clinical trials. BMJ, The, 2020, 368, m229.	3.0	10
47	Protocol for a systematic review of N-of-1 trial protocol guidelines and protocol reporting guidelines. Systematic Reviews, 2017, 6, 132.	2.5	9
48	Skin cancer screening after solid organ transplantation: Survey of practices in Canada. American Journal of Transplantation, 2019, 19, 1792-1797.	2.6	9
49	What Is Known About the Psychodermatology Clinic Model of Care? A Systematic Scoping Review. Journal of Cutaneous Medicine and Surgery, 2018, 22, 44-50.	0.6	8
50	Guidance for reporting outcomes in clinical trials: scoping review protocol. BMJ Open, 2019, 9, e023001.	0.8	8
51	Melanoma incidence, stage, and survival after solid organ transplant: A population-based cohort study in Ontario, Canada. Journal of the American Academy of Dermatology, 2020, 83, 754-761.	0.6	8
52	Research: increasing value, reducing waste – Authors' reply. Lancet, The, 2014, 383, 1126-1127.	6.3	7
53	Transparency in clinical trial reporting. BMJ: British Medical Journal, 2018, 363, k4224.	2.4	6
54	Selective outcome reporting across psychopharmacotherapy randomized controlled trials. International Journal of Methods in Psychiatric Research, 2022, 31, e1900.	1.1	5

#	Article	IF	Citations
55	A study protocol for the development of a SPIRIT extension for trials conducted using cohorts and routinely collected data (SPIRIT-ROUTINE). HRB Open Research, 2021, 4, 82.	0.3	4
56	Cutaneous signs and risk factors for ocular melanoma. Journal of the American Academy of Dermatology, 2021, 84, 1732-1734.	0.6	3
57	Accuracy of Algorithms to Identify People with Atopic Dermatitis in Ontario Routinely Collected Health Databases. Journal of Investigative Dermatology, 2021, 141, 1840-1843.	0.3	3
58	Reporting of methodological studies in health research: a protocol for the development of the Methodological STudy reporting Checklist (MISTIC). BMJ Open, 2020, 10, e040478.	0.8	3
59	Tips and tricks for understanding and using SR results. No 5: Prospective Trial Registers. Evidence-Based Child Health: A Cochrane Review Journal, 2007, 2, 536-537.	2.0	2
60	Treatment for Lentigo Maligna of the Head and Neck: Survey of Practices in Ontario, Canada. Dermatologic Surgery, 2018, 44, 918-923.	0.4	2
61	Outcomes of Staged Excision With Circumferential en Face Margin Control for Lentigo Maligna of the Head and Neck. Journal of Cutaneous Medicine and Surgery, 2021, 25, 18-24.	0.6	2
62	Restructuring Skin Cancer Care in Ontario: A Provincial Plan. Current Oncology, 2021, 28, 1183-1196.	0.9	1
63	The authors reply to: "Antihypertensives and skin cancer―and "Association between thiazide diuretics and skin cancer: still nebulous― Cmaj, 2021, 193, E964-E964.	0.9	1
64	Acute graft-versus-host disease after double lung transplantation. JAAD Case Reports, 2021, 13, 62-64.	0.4	1
65	Outcomes of skin cancers in pediatric solid organ transplant patients: A systematic review. Pediatric Transplantation, 2022, 26, e14146.	0.5	1
66	Reporting of primary outcome measures and sample size calculations in randomized controlled trials in dermatology journals. Journal of the American Academy of Dermatology, 2021, , .	0.6	1
67	Sociodemographic characteristics and emergency department visits and inpatient hospitalizations for atopic dermatitis in Ontario: a cross-sectional study. CMAJ Open, 2022, 10, E491-E499.	1.1	1
68	NoninferiorityÂRandomized Controlled Trials. Journal of Investigative Dermatology, 2022, 142, 1773-1777.	0.3	1
69	SPIRIT promotes protocol sharing. Lancet Psychiatry,the, 2018, 5, 390-391.	3.7	0
70	Characterization of discontinuation and nonpublication of phase 3 randomized clinical trials for psoriasis. British Journal of Dermatology, 2022, , .	1.4	0
71	Incidence of and Risk Factors for Keratinocyte Carcinoma After Pediatric Solid Organ Transplant. JAMA Dermatology, 0, , .	2.0	0